Drug recall · October 27, 2021
Imipramine Pamoate Capsules 125 mg recall
Why: Out of specification result observed in a dissolution test at the 9-month long term stability time point.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Imipramine Pamoate Capsules 125 mg, 30-count bottle, Rx only, Manufactured for Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 UNited States. Manufactured by: Lupin Limited, Pithampur, (M.P.) 454 775 India NDC# 68180-316-06
- Lots / codes
lot H002205, exp. date 08/2023
- Quantity
- 1,902 bottles
- Company
- Lupin Pharmaceuticals Inc., Baltimore, MD
- Distribution
- Distributed Nationwide in the USA.
- Initiated
- October 8, 2021 · Voluntary: Firm initiated
- Classified
- October 22, 2021
- Reported
- October 27, 2021
- Ended
- March 13, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Imipramine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.